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c-Abl is a non-receptor tyrosine kinase that is related to Src-
homology domains 2 and 3 (SH2 and SH3) protein kinases (Wang,
1993). The finding that c-Abl associates with the retinoblastoma
(Rb) protein has supported a role for c-Abl kinase in regulating the
cell cycle (Kipreos and Wang, 1992). Other studies have demon-
strated that c-Abl kinase phosphorylates the C-terminal domain 
of RNA polymerase II (Baskaran et al, 1996) and stimulates
transcription (Kipreos and Wang, 1992).
Recent work has demonstrated that DNA damage induced by a
variety of agents, including ionizing radiation, cisplatin, mito-
mycin C, methyl methane sulfonate, and cytarabine results in acti-
vation of c-Abl kinase (Kharbanda et al, 1995a; 1995b; Liu et al,
1996; Nehme et al, 1997). In response to DNA damage, c-Abl
associates with DNA-dependent protein kinase (DNA-PK) and is
activated by DNA-PK-dependent phosphorylation. Components
of the DNA-PK complex are involved in the sensing and repair of
DNA double-strand breaks.
The ATM protein has been shown to serve as an important link
between DNA damage and activation of c-Abl kinase (Baskaran 
et al, 1997; Shafman et al, 1997). When cells are treated with
ionizing radiation, c-Abl is activated, but only in the presence of
functional ATM. The association between ATM and c-Abl seems
to be constitutive; however, ATM activates c-Abl tyrosine kinase
activity only following DNA damage.
Activation of c-Abl kinase has been shown to directly
contribute to the regulation of growth arrest induced by ionizing
radiation (Yuan et al, 1996). c-Abl has been found to interact with
p53 and Rb (Goga et al, 1995; Welch and Wang, 1993). c-Abl acti-
vates the transactivation function of p53 and thus stimulates the
induction of p21WAF1 (Goga et al, 1995). In response to DNA
damage, c-Abl contributes to growth arrest by a p53-dependent
and p21WAF1-independent mechanism (Kharbanda et al, 1998).
It was our hypothesis that DNA damage and microtubule damage
result in activation of similar signaling pathways. Since DNA
damage activates c-Abl kinase, we asked whether c-Abl kinase is
involved in the signaling cascade activated by microtubule damage.
We therefore determined the effects of the microtubule-damaging
agent paclitaxel on c-Abl kinase and other signaling pathways. In
addition, we investigated the effects of c-Abl kinase on paclitaxel
toxicity and on paclitaxel-induced G2/M arrest.
MATERIALS AND METHODS
Cell culture
c-abl-null mouse fibroblasts (3T3-Abl–/– cells), polyclonal popula-
tions of reconstituted 3T3-Abl+ cells, and 3T3 mock infected cells
(3T3-mock cells) were obtained from Dr JYJ Wang (Wang, 1993).
3T3-Abl+ and 3T3-mock cells were obtained by infection and
selection of 3T3-Abl–/– cells with c-abl or empty recombinant
retroviruses containing the hygromycin-resistance gene. 3T3-
mock cells were used as a negative control in all experiments.
All cell lines were maintained in Dulbecco’s modified Eagle’s
medium (Irvine Scientific, Irvine CA, USA) supplemented with
100 mM L-glutamine and 10% heat-inactivated foetal bovine
serum. The absence and presence of expression of c-Abl in 3T3-
Abl–/–, 3T3-mock, and 3T3-Abl+ fibroblasts was verified by
immunoblot analysis (data not shown).
Reagents
Paclitaxel, vinblastine, vincristine, etoposide, and doxorubic-
in were purchased from Sigma Chemical Co (St. Louis MO,
USA) and dissolved in DMSO. Docetaxel was purchased from 
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USA), and was prepared as a 50 mM stock solution in polysorbate
80. Vinorelbine was obtained from Glaxo Wellcome Inc (Research
Triangle Park NC, USA), a stock solution of 9.26 mM was
prepared in water. Cisplatin was obtained from Bristol-Myers
Squibb Co (Princeton NJ, USA). Cisplatin was dissolved in 0.9%
NaCl as 3.33 mM stock solution.
Growth rate assay
Since 3T3 cells do not form discrete colonies, sulforhodamine
B growth rate assays were performed. Fibroblasts were seeded
into 96-well plates at a density of 1500 cells well–1 in 100 ml med-
ium. After 24 h, drugs were added in a final volume of 100 ml
medium, and cells were exposed to microtubule-damaging agents
for 24 h. Cells were allowed to grow for an additional 72 h after the
beginning of drug exposure. Cell growth was stopped by adding 50
ml of 50% (w/v) trichloroacetic acid, and cellular proteins were
stained with sulforhodamine B (Sigma Chemical Co) and measured
by spectrophotometry (Skehan et al, 1990). Control plates were
fixed to estimate the amount of cellular proteins at time 0. The rela-
tive growth rate, r, was calculated as reported previously (Monks et
al, 1991). Each experiment was performed in triplicate, and IC50
values were estimated by linear interpolation at r = 0.5. The growth
rates of untreated Abl-proficient and -deficient cells were identical.
Quantitation of apoptotic cells
3T3 cells were treated with 160 nM paclitaxel for 24 h. 72 h after
treatment, cells were collected by trypsinization and resuspended
in PBS containing 4 mg ml–1 acridine orange and 4 mg ml–1
ethidium bromide. Subsequently, cells were assessed for apoptotic
morphology by supravital fluorescence microscopy. Cells were
scored as apoptotic according to established morphologic criteria
(McGahon et al, 1995).
Cell cycle phase distribution
Approximately 1–2 ´ 106 cells were exposed to an equimolar
concentration of 160 nM paclitaxel for 24 h. This corresponded to
an IC40 and an IC70 concentration in 3T3-mock cells and 3T3-Abl+
cells, respectively. At 0, 1, 2, 3, 4, 5 and 6 days after starting pacli-
taxel treatment, cells were harvested by trypsinization, washed
twice with ice-cold PBS, and fixed in ice-cold 70% ethanol at a
concentration of 106 cells ml–1. Cells were counted and 106 cells
per sample were centrifuged, resuspended in 300 ml of ice-cold
PBS and treated with 0.1 mg ml–1 RNase A (Sigma Chemical Co)
at 37°C for 30 min. Propidium iodide (Molecular Probes, Eugene
OR, USA) at a final concentration of 50 mg ml–1 was then added to
the cell suspensions. After a 30 min incubation on ice, cells were
analysed on a FACScan flow cytometer (Becton-Dickinson, San
Jose CA, USA). Multicycle AV Cell Cycle software (Phoenix
Flow Systems, San Diego CA, USA) was used to calculate the
fraction of cells in each phase of the cell cycle, as described
previously by Dean and Jett (1974).
In vitro immune complex kinase assay for c-Abl kinase
Cells were grown to approximately 80% confluence and treated
with an equimolar concentration of 160 nM paclitaxel for 24 h. At
12 and 24 h after the beginning of exposure to paclitaxel, cells
were lysed in 1 ml lysis buffer (10 mM Tris-HCL (pH 7.4), 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 5 mM DTT, 
1 mM sodium vanadate, 0.1 mM phenylmethylsulfonyl fluoride,
and 5 mM aminocaproic acid) for 30 min on ice. The insoluble
material was removed by centrifugation at 30 000 g for 20 min 
at 4°C. Equal amounts of protein were incubated with protein 
A-Sepharose and anti-Abl (2.5 mg) (K-12, Santa Cruz Bio-
technology, Santa Cruz CA, USA) for 3 h at 4°C. Anti-Abl im-
mune complexes were washed twice with lysis buffer (500 mM
NaCl, lysis buffer/100 mM NaCl) and twice with kinase buffer
(25 mM Tris-HCl (pH 7.4), 10 mM MgCl2, and 1 mM DTT). The
washed pellet was resuspended in 20 ml of kinase buffer with 
50 mCi (g-32P) ATP (3000 Ci mmol–1), 10 mM cold ATP and 1 mg
of GST-CTD as substrate and incubated for 30 min at room
temperature (Baskaran et al, 1996). Reactions were terminated by
the addition of the SDS sample buffer and boiling for 5 min. The
phosphorylated proteins were resolved by 5–15% SDS-PAGE and
visualized by autoradiography. The amounts of c-Abl protein in
the anti-Abl immunoprecipitates were analysed by immuno-
blotting with anti-Abl (8E9; Pharmingen, San Diego CA, USA).
The antigen–antibody complexes were visualized by enhanced
chemiluminescence.
Western blotting
Cells growing in log phase were treated with 160 nM paclitaxel for
24 h. At various points in time, cells were lysed in 100 ml lysis
buffer as described above. 50 mg of total protein were subjected to
electrophoresis on 8%, 15%, or 10% polyacrylamide gels, for
analysis of phosphorylated MAPK, p21WAF1 and p53, respectively.
Cellular proteins were transferred to a polyvinylidene difluoride
membrane (Immobilon P; Millipore, Bedford MA, USA) by
electroblotting. Membranes were exposed to polyclonal anti-
phospho-MAPK antibody (New England Biolaboratories Inc,
Beverly MA, USA), polyclonal anti-p21WAF1 antibody (Santa Cruz
Biotechnology, Santa Cruz CA, USA), or monoclonal anti-p53
antibody (Santa Cruz Biotechnology), diluted 1: 1000 in 3–5%
bovine serum albumin. After washing, blots were exposed to
horseradish peroxidase-conjugated anti-rabbit or anti-mouse anti-
bodies diluted 1:3000 (Amersham Life Science Inc, Arlington
Heights IL, USA) and the complexes were visualized by enhanced
chemiluminescence.
RESULTS
Effect of paclitaxel on c-Abl kinase activity
DNA damage has been shown to activate c-Abl tyrosine kinase
(Kharbanda et al, 1995a; 1995b; Liu et al, 1996; Nehme et al,
1997). We were interested in whether c-Abl tyrosine kinase is also
involved in the cellular response to microtubule damage. 3T3-
mock and 3T3-Abl+ cells were treated with 160 nM paclitaxel for
24 h, and anti-Abl immunoprecipitates were prepared from cell
lysates at 12, and 24 h. In vitro kinase assays were performed with
the GST-CTD protein as substrate (Baskaran et al, 1996). GST-
CTD phosphorylation was not detectable in untreated cells (Figure 1).
In Abl-proficient cells, treatment with paclitaxel resulted in activa-
tion of c-Abl kinase at 12 and 24 h. As expected, paclitaxel did not
activate c-Abl kinase in Abl-deficient cells. Paclitaxel had no
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1, lower panel).
Effect of c-Abl kinase on paclitaxel sensitivity
In order to understand the role of c-Abl in the cellular response to
microtubule damage, we determined the effect of c-Abl kinase on the
sensitivity of 3T3 cells to microtubule-damaging agents (Table 1 and
Figure 2). Abl-proficient cells were 3.7 ± 0.5-fold more sensitive to
paclitaxel relative to Abl-deficient cells (IC5070 ±20 vs 260 ±50 nM,
mean ± SD, n = 4; P = 0.004 by two-sided t-test). The effect of c-Abl
on the sensitivity of 3T3 cells to docetaxel was much less marked and
was not statistically significant. The presence of c-Abl kinase had no
significant effect on the sensitivity of 3T3 cells to other microtubule-
damaging agents, including vincristine, vinblastine, and vinorelbine.
Similarly, c-Abl kinase had no effect on the sensitivity of 3T3 cells to
cisplatin, etoposide and doxorubicin (data not shown).
Effect of c-Abl kinase on paclitaxel-induced apoptosis
Paclitaxel has been shown to induce apoptosis in fibroblasts and
tumour cells (Fan, 1999). We have confirmed that paclitaxel triggers
apoptosis in 3T3 cells by demonstrating paclitaxel-induced cleavage
of poly (ADP-ribose) polymerase (PARP), a substrate for caspase 3
(Nicholson et al, 1995) (data not shown). In order to determine the
effect of c-Abl kinase on paclitaxel-induced apoptosis, 3T3-mock
and 3T3-Abl+ cells were treated with 160 nM paclitaxel for 24 h and
apoptotic cells were quantitated 72 h after the beginning of drug
exposure. The presence of c-Abl resulted in a 1.9 ± 0.3 (mean ±
SD)-fold increase in apoptotic cells in response to paclitaxel
treatment (n = 3, P = 0.03 by two-sided t-test). Interestingly, c-Abl
had no effect on the number of apoptotic cells in response to treat-
ment with 4 nM docetaxel for 24 h (data not shown).
Effect of c-Abl kinase and paclitaxel on cell cycle phase
distribution
In order to understand the mechanism(s) by which c-Abl kinase
regulates the sensitivity to paclitaxel, we determined the effect of
paclitaxel on cell cycle phase distribution in Abl-proficient and -
deficient cells (Figure 3). Cells were exposed to 160 nM paclitaxel
for 24 h which corresponded to an IC40 and an IC70 concentration
in 3T3-mock and 3T3-Abl+ cells, respectively. Paclitaxel caused a
marked G2/M arrest which peaked at 24 h after the beginning of
drug exposure. At 24 h, the fraction of cells in G2/M phase was 82
± 9% and 74 ± 12% in Abl-proficient and Abl-deficient cells,
respectively (mean ± SD, n = 3, P < 0.005 by two-sided t-test). In
Abl-proficient cells, the G2/M arrest persisted for a considerably
longer period of time relative to Abl-deficient cells. The difference
in the fraction of G2/M cells between Abl-proficient and Abl-defi-
cient cells was most marked at 6 days after starting exposure to
paclitaxel (66 ± 6% vs 32 ± 5%, mean ± SD, n = 3, P = 0.002 by
two-sided t-test).
Effect of c-Abl kinase on paclitaxel-induced G2/M arrest
In order to better quantitate the effect of c-Abl kinase on pacli-
taxel-induced G2/M arrest, we calculated the area under the curve
for fraction of cells in each phase of the cell cycle over time
(percent ´ days). The AUC for the G2/M phase of paclitaxel
treated cells was 260 ± 40 and 400 ± 30 (percent of cells in G2/M
phase ´ days, mean ± SD) in Abl-deficient and Abl-proficient
cells, respectively (Figure 4). This represents a 1.6 ± 0.2-fold
difference in AUC which is statistically significant (n = 3, P =
0.008, by two-sided t-test).
Effect of c-Abl kinase and paclitaxel on p21WAF1
expression
Paclitaxel has been reported to induce p21WAF1 (Blagosklonny et al,
1995), a protein known to be a general inhibitor of cyclin-depen-
dent kinases and a modulator of proliferating-cell-nuclear antigen
activity (Harper et al, 1993; Hunter and Pines, 1994). Therefore,
we investigated the effect of paclitaxel on the level of expression
of p21WAF1 in 3T3-mock and 3T3-Abl+ cells (Figure 5). p21WAF1
expression was determined by immunoblotting using an anti-
p21WAF1 antibody. Cells were exposed to an equimolar concen-
tration of paclitaxel (160 nM) for 24 h. In Abl-proficient cells,
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Figure 1 Effect of paclitaxel on c-Abl kinase activity. 3T3 cells were
exposed to 160 nM paclitaxel and harvested at 12 and 24 h after the
beginning of drug exposure. Time point 0 h represents untreated control
cells. Upper panel, activation of c-Abl determined by an immune complex
kinase assay with GST-CTD as the substrate. Lower panel, Western blot
analysis using an anti-Abl antibody. The experiment was repeated three
times with similar results
Table 1 Effect of the c-Abl kinase on drug sensitivity. The sulforhodamine B growth-rate assay was used to generate dose–response curves.
Results represent mean ± SD of at least three independent experiments performed with triplicate cultures. The dose-modifying factor represents
the ratio of the IC50 values of 3T3-mock over 3T3-Abl+ cells. IC50 values were compared by two-sided t-test
Drug Exposure time 3T3-mock cells 3T3-Abl+ cells Dose-modifying P-value
(h) (IC50) (IC50) factor
Paclitaxel (nM) 24 260 ± 50 70 ± 20 3.7 ± 0.5 0.004
Docetaxel (nM) 24 4.1 ± 1.6 3.8 ± 1.2 1.1 ± 0.3 0.808
Vinblastine (nM) 24 43 ± 5 33 ± 8 1.3 ± 0.4 0.14
Vincristine (mM) 24 1.8 ± 0.4 1.5 ± 0.5 1.2 ± 0.3 0.46
Vinorelbine (nM) 24 85 ± 15 77 ± 21 1.1 ± 0.2 0.62paclitaxel caused a rapid and marked induction of p21WAF1 which
peaked at 24 h. In Abl-deficient cells, however, paclitaxel had no
effect on the level of expression of p21WAF1 at 24 h; at later points
in time, overexpression of p21WAF1 was observed.
Effect of c-Abl kinase and paclitaxel on p53 expression
p53 has been shown to regulate the expression of p21WAF1 (El-
Deiry et al, 1993). In paclitaxel-treated HCT-116 cells, p53 expres-
sion remained unchanged during the first 6 h, increased at 12 and
18 h, peaked at 24 h, and subsequently decreased rapidly (Stewart
et al, 1999). To determine whether induction of p53 was required
for paclitaxel-induced overexpression of p21WAF1, we examined the
effect of paclitaxel on p53 expression in 3T3-mock and 3T3-Abl+
cells (Figure 5). Cells were exposed to 160 nM paclitaxel for 24 h
and cell lysates prepared at 24, 48, and 72 h were examined for
p53 protein levels using an anti-p53 antibody. In three separate
experiments paclitaxel had no significant effect on p53 expression
in 3T3-mock and 3T3-Abl+ cells.
Effect of c-Abl kinase and paclitaxel on MAPK activity
Paclitaxel has been shown to activate MAPK without altering the
level of MAPK expression (Ding et al, 1996; Wang et al, 1998;
Shtil et al, 1999). MAPK has been shown to be an upstream regu-
lator of p21WAF1 (Blagosklonny et al, 1995). We therefore investi-
gated the effect of c-Abl kinase and paclitaxel on MAPK activity
in 3T3-mock and 3T3-Abl+ cells (Figure 5). MAPK activity was
determined by immunoblotting using an antibody directed against
the phosphorylated form of MAPK. The fully phosphorylated
MAPK protein served as a positive control. Cells were exposed to
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Figure 2 Effect of c-Abl kinase on drug sensitivity. The sulforhodamine B
growth-rate assay was used to determine the effect of anticancer drugs in
3T3 cells. l = 3T3-Abl+ cells; l l = 3T3-mock cells. Data points represent
mean ± SD of at least three independent experiments performed with
triplicate cultures
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Figure 3 Effect of c-Abl kinase and paclitaxel on cell-cycle phase
distribution. Cells were exposed to 160 nM paclitaxel for 24 h and harvested
at the indicated times. The cell cycle phase distribution was determined by
flow cytometry. Data points represent mean ± SD of three different
experiments
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Figure 4 Effect of c-Abl kinase on paclitaxel-induced G2/M arrest. Each
phase of the cell cycle is expressed as the area under the curve of fraction of
cells over time (percent ´ days). The AUC for the G2/M phase was 1.6 ± 0.2-
fold larger in paclitaxel-treated Abl-proficient cells relative to paclitaxel-
treated Abl-deficient cells (n = 3, P = 0.008, by two-sided t-test). Columns
represent mean ± SD of three different experiments160 nM paclitaxel for 24 h. Paclitaxel had no effect on MAPK
phosphorylation in 3T3-mock and 3T3-Abl+ cells. These findings
indicate that, in 3T3 cells, upregulation of p21WAF1 by paclitaxel is
mediated by a pathway that is independent of MAPK.
DISCUSSION
DNA damage caused by ionizing radiation and other DNA-
damaging agents has been shown to result in activation of the 
c-Abl tyrosine kinase (Baskaran et al, 1997; Shafman et al, 1997).
We now report that, in addition to DNA damage, microtubule
damage induced by paclitaxel results in activation of c-Abl kinase.
Even though both DNA damage and microtubule damage activate
c-Abl kinase, the signaling pathways activated by the two types of
cellular injury differ in several respects. For instance, in 3T3 cells,
DNA-damaging agents activate the MAPK pathway (Nehme et al,
1997), whereas paclitaxel-induced microtubule damage did not.
Recent work has provided some insight related to the mecha-
nism(s) by which DNA damage is detected. We have previously
shown that activation of JNK and c-Abl by cisplatin is dependent
on the integrity of DNA mismatch repair function, indicating that
DNA mismatch repair proteins serve as a detector for DNA
damage due to cisplatin (Nehme et al, 1997). The mechanism by
which microtubule damage is detected, and the more upstream
events that lead to activation of c-Abl in response to microtubule
damage, are not understood.
In order to investigate the role of c-Abl in the cellular response
to microtubule damage, we determined the effect of c-Abl kinase
on the sensitivity of 3T3 cells to microtubule-damaging agents and
found that loss of c-Abl kinase confers resistance to paclitaxel.
Several mechanisms of acquired paclitaxel resistance have been
described in cells made resistant by prolonged treatment at low
drug concentrations. Paclitaxel-resistant CHO cells with struc-
turally altered a and/or b tubulin and impaired ability to poly-
merize tubulin dimers into microtubules have been described
(Cabral and Barlow, 1991). A second mechanism of acquired
paclitaxel resistance fits the general pattern of multiple drug
resistance (MDR) (Horwitz et al, 1993). Our results indicate that
loss of c-Abl kinase is another mechanism resulting in resistance
to paclitaxel.
Interestingly, c-Abl had no effect on the sensitivity of 3T3 cells
to docetaxel. This finding is intriguing, since the chemical struc-
tures of paclitaxel and docetaxel are very similar, and since both
are anti-microtubule agents that promote accelerated assembly of
excessively stable microtubules, thus affecting microtubule-
dependent cellular functions like the control of mitosis and intra-
cellular transport (Rowinsky and Donehower, 1996). However, the
two taxanes differ in several respects. Docetaxel has a higher
affinity for microtubules compared with paclitaxel (Lavelle et al,
1995). In preclinical models, paclitaxel and docetaxel differ with
respect to in vitro cytotoxicity and tumour cell-kill in xenograft
models (Schimming et al, 1999). Furthermore, in prostate cancer
cells, docetaxel is capable of inducing bcl-2 phosphorylation and
apoptotic cell death at 100-fold lower concentrations than pacli-
taxel (Haldar et al, 1997).
In addition to regulating the sensitivity of 3T3 cells to pacli-
taxel, c-Abl had marked effects on the cell cycle arrest induced by
paclitaxel. In Abl-proficient cells, paclitaxel induced a marked and
prolonged G2/M arrest. In Abl-deficient cells, paclitaxel induced a
G2/M arrest that was much less pronounced and considerably
shorter in duration. The presence of c-Abl kinase resulted in a 1.6-
fold increase in paclitaxel-induced G2/M arrest, as quantitated by
the ratio of the area under the curve of the fraction of cells in G2/M
phase over time, indicating that the extent and duration of the
paclitaxel-induced G2/M arrest are dependent on c-Abl tyrosine
kinase activity.
In order to understand the mechanism by which c-Abl regulates
the G2/M arrest caused by microtubule damage, we determined
the effect of c-Abl and paclitaxel on p21WAF1 expression. In Abl-
proficient cells, paclitaxel caused a rapid and marked induction of
p21WAF1 which peaked at 24 h. Similar time courses of p21WAF1
induction by paclitaxel have been described in human breast and
prostate cancer cells (Blagosklonny et al, 1995). In Abl-proficient
cells, the time course of paclitaxel-induced overexpression of
p21WAF1 corresponded well with the time course of paclitaxel-
induced G2/M arrest which both peaked at 24 h. In Abl-deficient
cells, paclitaxel caused no overexpression of p21WAF1 at 24 h;
however, at later points in time, overexpression of p21WAF1 was
observed. These findings indicate that c-Abl promotes the G2/M
arrest in response to paclitaxel-induced microtubule damage by
regulating the expression of p21WAF1.
In Abl-deficient cells, paclitaxel caused a G2/M arrest at 24 h
without inducing p21WAF1 expression. This observation can be
explained by the activation of pathways that are independent of c-
Abl and p21WAF1. For instance, cellular injury has been shown to
induce the ATM-mediated phosphorylation of chk2 as well as
phosphorylation of chk1, both of which phosphorylate cdc25C,
promoting its cytoplasmic sequestration (Shapirow and Harper,
1999). As a consequence, cdc25C cannot dephosphorylate cdc2,
which remains in an inactive state, resulting in G2/M arrest.
The increase in p21 level at 48 and 72 h in paclitaxel-treated,
Abl-deficient cells can be explained by the activation of Abl-
independent pathways. For instance, increased p21WAF1 mRNA
stability has been demonstrated in RKO cells following cellular
injury (Wang et al, 2000). Investigation into the mechanisms
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Figure 5 Effect of c-Abl kinase and paclitaxel on p21WAF1 and p53
expression and MAPK phosphorylation. Cells were exposed to 160 nM
paclitaxel for 24 h and harvested at the indicated times after the beginning of
drug exposure. Time-point 0 h represents untreated control cells. Cellular
proteins were analysed by SDS PAGE and Western blotting using antibodies
against p21WAF1, p53 and the phosphorylated form of MAPK. The fully
phosphorylated MAPK protein was used as a positive control (+).
Experiments were repeated three times with similar resultsunderlying this stabilization process revealed that proteins present
in cytoplasmic lysates formed complexes with p21WAF1 mRNA that
were inducible in response to cellular injury. The RNA-binding
protein HuR was identified within p21 mRNA–protein complexes
(Wang et al, 2000).
In 3T3 cells, induction of p21WAF1 by paclitaxel was not associ-
ated with overexpression of p53. This finding is in line with 
other reports, indicating that p21WAF1 may be induced by p53-
independent pathways. For instance, p53-independent induction 
of p21WAF1 was observed in other cell lines, including breast and
prostate carcinoma cells treated with paclitaxel (Blagosklonny et
al, 1995), human breast carcinoma cells treated with etoposide
(Sheikh et al, 1994), HaCat cells exposed to transforming growth
factor b (Datto et al, 1995), and in KG-1 cells treated with g-rays
or tumour-necrosis factor a (Akashi et al, 1995).
One potential mechanism by which paclitaxel regulates the
expression of p21WAF1 is the MAPK signaling pathway. Two recent
studies have reported that activation of the MAPK protein is
involved in induction of p21WAF1 in response to oxidative stress
(Esposito et al, 1997), and to paclitaxel (Blagosklonny et al, 1995).
Raf-1 kinase, a principal upstream regulator of MAPK activity, has
been shown to be responsible for paclitaxel-induced overexpres-
sion of p21WAF1 (Blagosklonny et al, 1995). However, our results in
3T3 cells show that induction of p21WAF1 by paclitaxel was not
mediated by the MAPK pathway, since paclitaxel had no signifi-
cant effect on MAPK phosphorylation.
We conclude that, in addition to DNA damage, paclitaxel-
induced microtubule damage results in activation of c-Abl kinase.
c-Abl kinase plays an important role in the cellular response to
microtubule damage; c-Abl kinase regulates the sensitivity of 3T3
cells to paclitaxel and regulates paclitaxel-induced G2/M arrest in
a pathway that is dependent on p21WAF1.
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